Viatris Inc. (VTRS)
Automate Your Wheel Strategy on VTRS
With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTRS
- Rev/Share 12.0069
- Book/Share 13.1251
- PB 0.6728
- Debt/Equity 0.9238
- CurrentRatio 1.6822
- ROIC -0.0935
- MktCap 10363594400.0
- FreeCF/Share 1.5592
- PFCF 5.5742
- PE -2.778
- Debt/Assets 0.3758
- DivYield 0.0544
- ROE -0.206
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Published: March 28, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS).
Read More
Viatris Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VTRS
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Viatris Inc. (VTRS)
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India. Hagens Berman is investigating possible misconduct concerning the timing of Viatris' disclosures and urges investors who purchased Viatris shares and suffered substantial losses to submit your losses now.
Read More
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS)
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
VTRS Investor News: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Viatris Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - VTRS
Published: March 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Shareholders That Lost Money on Viatris Inc.(VTRS) Should Contact Levi & Korsinsky about Securities Fraud Investigation - VTRS
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India.
Read More
Viatris Inc. (VTRS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc.(NASDAQ:VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viatris Inc. (VTRS) Regarding Possible Securities Fraud Violations
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Did Viatris Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VTRS
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ:VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
Read More
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS)
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Published: March 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: March 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Shareholders that lost money on Viatris Inc.(VTRS) should contact Levi & Korsinsky about Securities Fraud Investigation - VTRS
Published: March 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility - Hagens Berman
Published: March 14, 2025 by: Accesswire
Sentiment: Neutral
VTRS Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESS Newswire / March 14, 2025 / On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ:VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India. Hagens Berman is investigating possible misconduct concerning the timing of Viatris' disclosures and urges investors who purchased Viatris shares and suffered substantial losses to submit your losses now.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Shareholders to Reach Out
Published: March 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS). Investors who purchased Viatris securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VTRS.
Read More
Investors who Lost Money on Viatris Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - VTRS
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Viatris Inc. (VTRS)
- IPO Date 1980-03-17
- Website https://www.viatris.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Scott Andrew Smith Ph.D.
- Employees 32000